LOS ANGELES, July 13 (Xinhua) -- Use of low-dose atropine eyedrops was no better than placebo at slowing myopia progression and elongation of the eye among children treated for two years, according to a new trial funded by the U.S. National Eye Institute (NEI).
Identifying an optimal approach for preventing advanced myopia is urgently needed given the escalating prevalence of myopia overall and the risk of it progressing to advanced myopia, according to the NEI.
